Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study

Hepatology

Volumn 64, Issue 6, 2016, Pages 1911-1921

  Martinello, Marianne ^a   Gane, Edward ^b   Hellard, Margaret ^c   Sasadeusz, Joe ^d   Shaw, David ^e   Petoumenos, Kathy ^a   Applegate, Tanya ^a   Grebely, Jason ^a   Maire, Laurence ^a   Marks, Philippa ^a   Dore, Gregory J ^a   Matthews, Gail V ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c BURNET INSTITUTE   (Australia)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

^e ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEMOGLOBIN; RIBAVIRIN; SOFOSBUVIR; VIRUS RNA; ANTIVIRUS AGENT;

ABDOMINAL PAIN; ACUTE HEPATITIS C; ADULT; ADULT DISEASE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASYMPTOMATIC INFECTION; AUSTRALIA AND NEW ZEALAND; BLOOD TOXICITY; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; DECOMPENSATED LIVER CIRRHOSIS; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 2B; HEPATITIS C VIRUS SUBTYPE 3A; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; JAUNDICE; MALE; MEDICATION COMPLIANCE; MIXED INFECTION; MULTICENTER STUDY; MUSCULOSKELETAL CHEST PAIN; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; OPEN STUDY; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RASH; REINFECTION; RELAPSE; SEROCONVERSION; SIDE EFFECT; SLEEP DISORDER; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; HEPATITIS C, CHRONIC; MIDDLE AGED; TIME FACTOR; TREATMENT FAILURE;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RIBAVIRIN; SOFOSBUVIR; TIME FACTORS; TREATMENT FAILURE;

EID: 84995807051     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28844     Document Type: Article

References (42)

1. Martinello M, Matthews GV. Enhancing the detection and management of acute hepatitis C virus infection. Int J Drug Policy 2015;26:899–910.
2. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015;63:199–236.
3. American Association for the Study of Liver Diseases, Infectious Diseases Society of American. Recommendations for testing, managing, and treating hepatitis C. 2015. http://www.hcvguidelines.org.
4. Dore GJ, Feld JJ. Hepatitis C virus therapeutic development: in pursuit of “perfectovir.” Clin Infect Dis 2015;60:1829–1836.
5. Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015;373:2599–2607.
6. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879–1888.
7. Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV 2015;2:e319–e327.
8. Gane EJ, Schwabe C, Hyland RH, Yang Y, Svarovskaia E, Stamm LM, et al. Efficacy of the combination of sofosbuvir, velpatasvir, and the NS3/4A protease inhibitor GS-9857 in treatment-naive or previously treated patients with HCV genotype 1 or 3 infections. Gastroenterology 2016;151:448–456.
9. Dore GJ, Hellard M, Matthews GV, Grebely J, Haber PS, Petoumenos K, et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010;138:123–135.
10. Martin NK, Thornton A, Hickman M, Sabin C, Nelson M, Cooke GS, et al. Can hepatitis C virus (HCV) direct-acting antiviral treatment as prevention reverse the HCV epidemic among men who have sex with men in the United Kingdom? Epidemiological and modeling insights. Clin Infect Dis 2016;62:1072–1080.
11. Martin NK, Vickerman P, Dore GJ, Hickman M. The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention. Curr Opin HIV AIDS 2015;10:374–380.
12. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013;368:34–44.
13. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014;370:1993–2001.
14. Molina JM, Orkin C, Iser DM, Zamora FX, Nelson M, Stephan C, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet 2015;385:1098–1106.
15. Hajarizadeh B, Grebely J, Dore GJ. Case definitions for acute hepatitis C virus infection: a systematic review. J Hepatol 2012;57:1349–1360.
16. Fleischer R, Boxwell D, Sherman K. Nucleoside analogues and mitochondrial toxicity. Clin Infect Dis 2004;38:e79–e80.
17. Alvarez D, Dieterich D, Brau N, Moores L, Ball L, Sulkowski M. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat 2006;13:683–689.
18. Sovaldi prescribing information. Foster City, CA: Gilead Sciences Inc.; 2015.
19. Jacka B, Applegate T, Krajden M, Olmstead A, Harrigan PR, Marshall BD, et al. Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada. Hepatology 2014;60:1571–1580.
20. Lamoury FM, Jacka B, Bartlett S, Bull RA, Wong A, Amin J, et al. The influence of hepatitis C virus genetic region on phylogenetic clustering analysis. PLoS One 2015;10:e0131437.
21. Eslam M, Hashem AM, Leung R, Romero-Gomez M, Berg T, Dore GJ, et al. Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat Commun 2015;6:6422.
22. Suppiah V, Gaudieri S, Armstrong NJ, O'Connor KS, Berg T, Weltman M, et al. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European cohort: a cross-sectional study. PLoS Med 2011;8:e1001092.
23. Darke S, Hall W, Wodak A, Heather N, Ward J. Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. Br J Addict 1992;87:733–742.
24. D'Avolio A, Ibanez A, Sciandra M, Siccardi M, de Requena DG, Bonora S, et al. Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients. J Chromatogr B Analyt Technol Biomed Life Sci 2006;835:127–130.
25. Fierer DS, Dieterich DT, Mullen MP, Branch AD, Uriel AJ, Carriero DC, et al. Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. Clin Infect Dis 2014;58:873–879.
26. Martinello M, Hellard M, Shaw D, Petoumenos K, Applegate T, Grebely J, et al. Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies. Antivir Ther 2016;21:465.
27. Foster GR, Afdhal N, Roberts SK, Brau N, Gane EJ, Pianko S, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015;373:2608–2617.
28. Deterding K, Spinner C, Schott E, Welzel T, Gerken G, Klinker H, et al. Six weeks of sofosbuvir/ledipasvir (SOF/LDV) are sufficient to treat acute hepatitis C virus genotype 1 monoinfection: the HEPNET Acute HCV IV Study [Abstract]. In: Proceedings of the 51st Annual Meeting of the European Association for the Study of the Liver; April 13-17, 2016; Barcelona, Spain. Abstract LBO8.
29. Basu P, Shah NJ, John N, Aloysius M, Brown R. Sofosbuvir and ledipasvir versus sofosbuvir and simeprevir combination therapy in the management of acute hepatitis C: a randomized open label prospective clinical pilot study. SLAM C study. Interim data. Hepatology 2015;62:736A.
30. Rockstroh JK, Bhagani S, Hyland RH, Yun C, Zheng W, Brainard DM, et al. Ledipasvir/sofosbuvir for 6 weeks in HIV-infected patients with acute HCV infection [Abstract]. In: Proceedings of the Conference on Opportunisitic Infections and Retroviruses; February 22-25, 2016; Boston, MA. Abstract 154LB3.
31. + men who have sex with men: a systematic review and meta-analysis. Int J STD AIDS 2016; doi: 10.1177/0956462416630910.
32. Hagan H, Jordan AE, Neurer J, Cleland CM. Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men. AIDS 2015;29:2335–2345.
33. Martin TC, Martin NK, Hickman M, Vickerman P, Page EE, Everett R, et al. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. AIDS 2013;27:2551–2557.
34. Lambers FA, Prins M, Thomas X, Molenkamp R, Kwa D, Brinkman K, et al. Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. AIDS 2011;25:F21–F27.
35. Ingiliz P, Krznaric I, Stellbrink HJ, Knecht G, Lutz T, Noah C, et al. Multiple hepatitis C virus (HCV) reinfections in HIV-positive men who have sex with men: no influence of HCV genotype switch or interleukin-28B genotype on spontaneous clearance. HIV Med 2014;15:355–361.
36. Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, et al. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. Annals of internal medicine. 2016 Aug 9. doi: 10.7326/M16-0816.
37. Doyle JS, Shaw D, Dore GJ, Grebely J, Erratt A, Hellard ME, et al. Low rates of re-infection and reduced injecting long-term following recently acquired HCV in the Australian trial of acute hepatitis C: the ATAHC recall study. In: Proceedings of AIDS 2014: 20th International AIDS Conference; July 20-25 2014; Melbourne, Australia. Abstract TUPDB0103.
38. Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 2013;57(Suppl. 2):S80–S89.
39. Bruneau J, Zang G, Abrahamowicz M, Jutras-Aswad D, Daniel M, Roy E. Sustained drug use changes after hepatitis C screening and counseling among recently infected persons who inject drugs: a longitudinal study. Clin Infect Dis 2014;58:755–761.
40. Hickman M, De Angelis D, Vickerman P, Hutchinson S, Martin NK. Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence. Curr Opin Infect Dis 2015;28:576–582.
41. Martin NK, Vickerman P, Dore GJ, Grebely J, Miners A, Cairns J, et al. Prioritization of HCV treatment in the direct-acting antiviral era: an economic evaluation. J Hepatol 2016;65:17–25.
42. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 2015;163:215–223.